A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug

Journal of Medicinal Chemistry

Volumn 40, Issue 13, 1997, Pages 2011-2016

  Bertolini, Giorgio ^a   Aquino, Mario ^a   Biffi, Mauro ^a   D'Atri, Gaetano ^a   Di Pierro, Francesco ^a   Ferrario, Francesco ^a   Mascagni, Paolo ^a   Somenzi, Flavio ^a   Zaliani, Andrea ^a   Leoni, Flavio ^a  

^a Italfarmaco SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; TERIFLUNOMIDE;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; DRUG CONFORMATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GLOMERULONEPHRITIS; GRAFT VERSUS HOST REACTION; HYPOTHESIS; IMMUNOSUPPRESSIVE TREATMENT; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANILINE COMPOUNDS; ANIMALS; FEMALE; HYDROXYBUTYRATES; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15644364861     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970039n     Document Type: Article

References (31)

1. Heubach, G.; Hoerlein, G.; Sachse, B. Fungicidal isoxazole derivatives. Ger. Pat. DE 2,525,023, 1975; Chem. Abstr. 1977, 86, 106569H.
2. Bartlett, R. R.; Dimitrijevic, M.; Mattar, T.; Zielinski, T.; Germann, T.; Rüde, E.; Thones, G. H.; Küchle, C. C. A.; Schorlemmer, H.-U.; Bremer, E.; Finnegan, A.; Schleyerbach, R. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991, 32, 10-21.
3. Thomson, A. W.; Starzi, T. E. New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Immunol. Rev. 1993, 136, 71-88.
4. Bartlett, R. R.; Schleyerbach, R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat. Int. J. Immunopharmacol. 1985, 7, 7-18.
5. Pasternak, R. D.; Wadopian, N. S.; Wright, R. N.; Siminoff, P.; Gylys, J. A.; Buyniski, J. P. Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis. Agents Actions 1987, 21, 241-243.
6. Popovic, S.; Bartlett, R. R. Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice. Agents Actions 1986, 19, 313-314.
7. Bartlett, R. R.; Popovic, S.; Raiss, R. X. Development of autoimmunity in MRL/lpr mice and the effect of drugs on the murine disease. Scand. J. Rheumatol. 1988, 75, 290-299.
8. Bartlett, R. R.; Mattar, T.; Weithmann, U.; Anagnostopulos, H.; Popovic, S.; Schleyerbach, R. Leflunomide (HWA 486): a novel immunorestoring drug. In Therapeutic approaches to inflammatory diseases; Lewis, A. J., Doherty, N. S., Ackerman, N. R., Eds.; Elsevier Science Publishing Co., Inc.: New York, 1989; pp 215-228.
9. Thoenes, G. H.; Sitter, T.; Langer, K. H.; Bartlett, R. R.; Schleyerbach, R. Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int. J. Immunopharmacol. 1989, 11, 921-929.
10. Ogawa, T.; Inazu, M.; Gotoh, K.; Hayashi, S. Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats. Agents Actions 1990, 31, 321-328.
11. Popovic, S.; Bartlett, R. R. The use of murine chronic graft versus host (CVGH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents Actions 1987, 21, 284-286.
12. Lang, R.; Wagner, H.; Heeg, K. Differential effects of the immunosuppressive agents cyclosporine and leflunomide in vivo. Transplantation 1995, 59, 382-389.
13. Parnham, M. J. Leflunomide: a potential new disease-modifying anti-rheumatic drug. Exp. Opin. Invest. Drugs 1995, 4, 777-779.
14. Bartlett, R. R.; Schleyerbach, R.; Kaemmerer, F. J. Drugs for the treatment of graft-versus-host and immune diseases. Ger Pat. DE 3 534 440, 1987; Chem. Abstr. 1987, 107, 861j.
15. Axton, C. A.; Billingham, M. E. J.; Bishop, P. M.; Gallagher, P. T.; Hicks, T. A.; Kitchen, E. A.; Mullier, G. W.; Owton, W. M.; Parry, M. G.; Scott, S.; Steggles, D.J. Novel immunosuppressive butenamides. J. Chem. Soc., Perkin Trans. 1 1992, 2203-2213.
16. Zielinski, T.; Muller, H. J.; Bartlett, R. R. Effects of Leflunomide (HWA 486) on expression of lymphocyte activation markers. Agents Actions 1993, 38, Special Conference Issue C80-C82.
17. Chong, A. S.-F.; Finnegan, A.; Jiang, X.; Gebel, H.; Sankary, H. N.; Foster, P.; Williams, J. W. Leflunomide, a novel immunosuppressive agent. Transplantation 1993, 55, 1361-1366.
18. Mattar, T.; Kochhar, K.; Bartlett, R.; Bremer, E. G.; Finnegan, A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS 1993, 334, 161-164.
19. Xu, X.; Williams, J. W.; Bremer, E. G.; Finnegan, A.; Chong, A. S.-F. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem. 1995, 270, 12398-12403.
20. Cherwinski, H. M.; McCarley, D.; Schatzman, R.; Devens, B.; Ransom, J. T. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J. Pharmacol. Exp. Ther. 1995, 272, 460-468.
21. Williamson, R. A.; Yea, C. M.; Robson, P. A.; Curnock, A. P.; Gadher, S.; Hambleton, A. B.; Woodward, K.; Bruneau, J. M.; Harableton, P.; Moss, D.; Thomson, T. A.; Spinella-Jaegle, S.; Morand, P.; Courtin, O.; Sautes, C.; Westwood, R.; Hercend, T.; Kuo, E. A.; Ruuth, E. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. 1995, 270, 22467-22472.
22. Davis, J. P.; Cain, G. A.; Pitts, W. J.; Magolda, R. L.; Copeland, R. A. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996, 35, 1270-1273.
23. Silva, H. T.; Morris, R. E. Leflunomide and malononitriloamides. Exp. Opin. Invest. Drugs 1997, 6, 51-64.
24. Stecher, V. J.; Carlson, J. A. Disease modifying anti-rheumatic drugs. Annu. Rep. Med. Chem. 1983, 18, 171-179.
25. Chiaffarino, F.; Biffi, M.; Luciano, A.; Gromo, G.; Leoni, F. Involvement of multiple protein kinases in CD3-mediated activation of human T lymphocytes. Cell. Immunol. 1994, 153, 39-51.
26. Waldmann, T. A. The structure, function nad expression of interleukin-2 receptors on normal and malignaant T cells. Science 1986, 232, 727-732.
27. Neckers, L. M. Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 3494-3498.
28. Zielinski, T.; Herrmann, M.; Muller, H.-J.; Riedel, N.; Burtlett R. R. The influence of leflunomide on cell cycle, Il-2-receptor (IL-2R) and its gene expression. Agents Actions 1994, 41, Special Conference Issue C204-C205.
29. Meuer, S. C.; Hussey, R. E.; Fabbi, M.; Fox, D.; Acuto, O.; Fitzgerald, K. A.; Hodgdon, J. C.; Protentis, J. P.; Schlossman, S. F.; Reinerz, E. L. An alternative pathway of T cell activation: a functional role for the 50kD T11 sheep erythrocyte receptor protein. Cell 1984, 36, 897-906.
30. Dustin, M. L.; Sanders, M. E.; Shaw, S.; Springer, T. A. Purified lymphocyte function associated antigen-3 (LFA3) binds to CD2 and mediates T-lymphocyte adhesion. J. Exp. Med. 1987, 165, 677-692.
31. Di Pierro, F.; d'Atri, G.; Marcucci, F.; Leoni, F. Use of type I and type IV hypersensitivity responses to define the immunopharmacological profile of drugs. J. Pharmacol. Toxicol. Methods 1997, in press.